CureVac Fails In Pivotal COVID-19 Vaccine Trial With 47% Efficacy

German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of...

from NDTV News - World-news